CLAIMS

1. A composition comprising a fusion protein comprising at least two cytokines,
   wherein the cytokines are CCL20 and IL-1β,
   wherein the IL-1β cytokine comprises a mutation and has reduced binding activity to its receptor, and the CCL20 cytokine is a wild type cytokine.
2. The composition according to claim 1, further comprising a GGS linker.
3. The composition of claim 1, wherein the IL-1β is human IL-1β, and wherein the mutation is selected from R120G, Q131G, H146A, Q148G, and K209A.
4. The composition of claim 3, wherein the mutation is Q148G.
5. The composition as in any of claims 1, 2, 3, or 4 for use as a medicament.
6. The composition as in any of claims 1, 2, 3, or 4, wherein the wild type cytokine provides cell-specific targeting that restores activity of the mutant cytokine on the targeted cells.